Title
Nasopharyngeal pneumococcal density during asymptomatic respiratory virus infection and risk for subsequent acute respiratory illness
Date Issued
01 January 2019
Access level
open access
Resource Type
journal article
Author(s)
Publisher(s)
Centers for Disease Control and Prevention (CDC)
Abstract
Increased nasopharyngeal pneumococcal (Streptococcus pneumoniae) colonization density has been associated with invasive pneumococcal disease, but factors that increase pneumococcal density are poorly understood. We evaluated pneumococcal densities in nasopharyngeal samples from asymptomatic young children from Peru and their association with subsequent acute respiratory illness (ARI). Total pneumococcal densities (encompassing all present serotypes) during asymptomatic periods were significantly higher when a respiratory virus was detected versus when no virus was detected (p<0.001). In adjusted analyses, increased pneumococcal density was significantly associated with the risk for a subsequent ARI (p<0.001), whereas asymptomatic viral detection alone was associated with lower risk for subsequent ARI. These findings suggest that interactions between viruses and pneumococci in the nasopharynx during asymptomatic periods might have a role in onset of subsequent ARI. The mechanisms for these interactions, along with other potentially associated host and environmental factors, and their role in ARI pathogenesis and pneumococcal transmission require further elucidation.
Start page
2040
End page
2047
Volume
25
Issue
11
Language
English
OCDE Knowledge area
Enfermedades infecciosas Sistema respiratorio
Scopus EID
2-s2.0-85073629615
PubMed ID
Source
Emerging Infectious Diseases
ISSN of the container
10806040
Sponsor(s)
This work was supported by the Vanderbilt University Clinical and Translational Science Award (grant no. UL1 RR024975-01) from the National Institutes of Health; investigator-initiated research grants (grant nos. IIR WS1898786 [0887X1-4492] and IIR WS2079099) from Pfizer; a grant from the Thrasher Research Fund (grant no. 02832-9); and funds from the Vanderbilt University Medical Center Department of Pediatrics Turner-Hazinski and Katherine Dodd Faculty Scholars Awards, the Vanderbilt Faculty Research Scholars Program, and the Pfizer Young Investigator in Vaccine Development award. J.E.V. received support from the National Institutes of Health (grant no. R21AI112768-01A1). L.M.H received funding support by the National Institutes of Health (K23 AI141621-02).
Sources of information: Directorio de Producción Científica Scopus